Author

Antonio Gasbarrini

REAL-WORLD COMPARATIVE EFFECTS OF THREE-IN-ONE SINGLE CAPSULE BISMUTH QUADRUPLE THERAPY VS. NON-BISMUTH QUADRUPLE CONCOMITANT THERAPY: INTERIM ANALYSIS OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
REAL-WORLD COMPARATIVE EFFECTS OF THREE-IN-ONE SINGLE CAPSULE BISMUTH QUADRUPLE THERAPY VS. NON-BISMUTH QUADRUPLE CONCOMITANT THERAPY: INTERIM ANALYSIS OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Antonio Gasbarrini  et al.

CHARACTERISTICS OF DONORS FOR FAECAL MICROBIOTA TRANSPLANTATION OF A HIGH-VOLUME STOOL BANK: A 7-YEAR EXPERIENCE
CHARACTERISTICS OF DONORS FOR FAECAL MICROBIOTA TRANSPLANTATION OF A HIGH-VOLUME STOOL BANK: A 7-YEAR EXPERIENCE

Antonio Gasbarrini  et al.

FAECAL MICROBIOTA TRANSPLANTATION FOR C. DIFFICILE INFECTION DURING THE COVID-19 PANDEMIC: DESCRIPTION OF A SECURITY PROGRAM WITH HIGH-SUCCESS RATE
FAECAL MICROBIOTA TRANSPLANTATION FOR C. DIFFICILE INFECTION DURING THE COVID-19 PANDEMIC: DESCRIPTION OF A SECURITY PROGRAM WITH HIGH-SUCCESS RATE

Antonio Gasbarrini  et al.

RADIOMICS COULD PREDICT SURGERY AT 10 YEARS IN CROHN’S DISEASE
RADIOMICS COULD PREDICT SURGERY AT 10 YEARS IN CROHN’S DISEASE

Antonio Gasbarrini  et al.

MULTIDISCIPLINARY APPROACH IN EOSINOPHILIC OESOPHAGITIS CARE: HOW TO IMPROVE DIAGNOSIS AND MANAGEMENT
MULTIDISCIPLINARY APPROACH IN EOSINOPHILIC OESOPHAGITIS CARE: HOW TO IMPROVE DIAGNOSIS AND MANAGEMENT

Antonio Gasbarrini  et al.

EFFECTIVENESS AND SAFETY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB FORMULATION IN INFLAMMATORY BOWEL DISEASE PATIENTS IN CLINICAL REMISSION: A SINGLE CENTRE REAL WORLD EXPERIENCE
EFFECTIVENESS AND SAFETY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB FORMULATION IN INFLAMMATORY BOWEL DISEASE PATIENTS IN CLINICAL REMISSION: A SINGLE CENTRE REAL WORLD EXPERIENCE

Antonio Gasbarrini  et al.

DUAL TARGETED THERAPY: A FUTURE STRATEGY FOR THE MANAGEMENT OF REFRACTORY INFLAMMATORY BOWEL DISEASE
DUAL TARGETED THERAPY: A FUTURE STRATEGY FOR THE MANAGEMENT OF REFRACTORY INFLAMMATORY BOWEL DISEASE

Antonio Gasbarrini  et al.

FIRST-LINE H. PYLORI ERADICATION THERAPY IN EUROPE: RESULTS FROM 24,882 CASES OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
FIRST-LINE H. PYLORI ERADICATION THERAPY IN EUROPE: RESULTS FROM 24,882 CASES OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Antonio Gasbarrini  et al.

TARGETING THE INTESTINAL ECOSYSTEM THROUGH A GUT MICROBIOME TESTING TO TREAT RECURRENT URINARY-TRACT INFECTIONS FROM GUT PATHOBIONTS: A PILOT STUDY
TARGETING THE INTESTINAL ECOSYSTEM THROUGH A GUT MICROBIOME TESTING TO TREAT RECURRENT URINARY-TRACT INFECTIONS FROM GUT PATHOBIONTS: A PILOT STUDY

Antonio Gasbarrini  et al.

SERIAL FECAL MICROBIOTA INFUSIONS BY COLONOSCOPY FOR ACTIVE ULCERATIVE COLITIS: A FEASIBILITY, SAFETY AND TRANSLATIONAL MONOCENTRIC ITALIAN STUDY
SERIAL FECAL MICROBIOTA INFUSIONS BY COLONOSCOPY FOR ACTIVE ULCERATIVE COLITIS: A FEASIBILITY, SAFETY AND TRANSLATIONAL MONOCENTRIC ITALIAN STUDY

Antonio Gasbarrini  et al.

A MICROBIOME TESTING-BASED PRECISION MEDICINE APPROACH TO TREAT POST-INFECTIOUS IRRITABLE BOWEL SYNDROME: A PILOT STUDY
A MICROBIOME TESTING-BASED PRECISION MEDICINE APPROACH TO TREAT POST-INFECTIOUS IRRITABLE BOWEL SYNDROME: A PILOT STUDY

Antonio Gasbarrini  et al.

SCREENING OF DONOR FECES WITH A DIRECT STOOL TESTING-BASED APPROACH: FRAMEWORK AND OUTCOMES OF A LARGE-VOLUME DONOR STOOL BIOBANK FOR FECAL MICROBIOTA TRANSPLANTATION
SCREENING OF DONOR FECES WITH A DIRECT STOOL TESTING-BASED APPROACH: FRAMEWORK AND OUTCOMES OF A LARGE-VOLUME DONOR STOOL BIOBANK FOR FECAL MICROBIOTA TRANSPLANTATION

Antonio Gasbarrini  et al.

EXPERIENCE WITH RIFABUTIN-CONTAINING THERAPY IN 426 PATIENTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
EXPERIENCE WITH RIFABUTIN-CONTAINING THERAPY IN 426 PATIENTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Antonio Gasbarrini  et al.

EFFECTIVENESS OF HELICOBACTER PYLORI TREATMENTS ACCORDING TO ANTIBIOTIC RESISTANCE: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
EFFECTIVENESS OF HELICOBACTER PYLORI TREATMENTS ACCORDING TO ANTIBIOTIC RESISTANCE: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Antonio Gasbarrini  et al.

EFFICACY AND SAFETY OF FECAL MICROBIOTA TRANSPLANTATION FOR THE TREATMENT OF SEVERE AND SEVERE-COMPLICATED CLOSTRIDIOIDES DIFFICILE INFECTION: REPORT FROM A LARGE-VOLUME FMT CENTER
EFFICACY AND SAFETY OF FECAL MICROBIOTA TRANSPLANTATION FOR THE TREATMENT OF SEVERE AND SEVERE-COMPLICATED CLOSTRIDIOIDES DIFFICILE INFECTION: REPORT FROM A LARGE-VOLUME FMT CENTER

Antonio Gasbarrini  et al.

EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG): EMPIRICAL FIRST-LINE TREATMENT USE AND EFFECTIVENESS TRENDS IN EUROPE IN THE PERIOD 2013-2020
EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG): EMPIRICAL FIRST-LINE TREATMENT USE AND EFFECTIVENESS TRENDS IN EUROPE IN THE PERIOD 2013-2020

Antonio Gasbarrini  et al.

URINARY LITHOGENIC PROFILE AND GUT AND URINARY MICROBIOTA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
URINARY LITHOGENIC PROFILE AND GUT AND URINARY MICROBIOTA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Antonio Gasbarrini  et al.

REAL-LIFE VS TRIAL ACCESS TO BIOLOGICAL THERAPY DIFFERENCES: A 2019-2020 EXPERIENCE IN AN ITALIAN TERTIARY IBD CENTER
REAL-LIFE VS TRIAL ACCESS TO BIOLOGICAL THERAPY DIFFERENCES: A 2019-2020 EXPERIENCE IN AN ITALIAN TERTIARY IBD CENTER

Antonio Gasbarrini  et al.

IMPACT OF HELICOBACTER PYLORI CLARITHROMYCIN RESISTANCE ON THE TREATMENT EFFECTIVENESS: DATA OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
IMPACT OF HELICOBACTER PYLORI CLARITHROMYCIN RESISTANCE ON THE TREATMENT EFFECTIVENESS: DATA OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Antonio Gasbarrini  et al.

HELICOBACTER PYLORI ANTIBIOTIC RESISTANCE: DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
HELICOBACTER PYLORI ANTIBIOTIC RESISTANCE: DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Antonio Gasbarrini  et al.

Item 41 - 60 / 85
1 2
3
4 5